HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

TSCA, “Badly In Need Of Reform,” Comes Under Congressional Scrutiny

This article was originally published in The Rose Sheet

Executive Summary

The House Energy and Commerce Committee's Subcommittee on Commerce, Trade and Consumer Protection is reviewing the Toxic Substances Control Act of 1976, a statute that is "badly in need of reform," Chairman Bobby Rush, D-Ill., said at a Feb. 26 hearing

You may also be interested in...



Chemical Safety Improvement Act Promises Stronger EPA Oversight

Introduced by New Jersey Sen. Frank Lautenberg, the Chemical Safety Improvement Act of 2013 would give EPA authority to evaluate chemicals in commerce based on risk to human health and the environment and take action on those deemed unsafe. The bill would update the current Toxic Substances Control Act and potentially impact manufacturers of cosmetic ingredients.

Council Celebrating Industry's Contribution To Economy At 2010 Meeting

The Personal Care Products Council will continue to focus on cosmetics legislation in 2010 while promoting the industry's positive impact on the U.S. economy and working to help members stay competitive in a trying market

Council Celebrating Industry's Contribution To Economy At 2010 Meeting

The Personal Care Products Council will continue to focus on cosmetics legislation in 2010 while promoting the industry's positive impact on the U.S. economy and working to help members stay competitive in a trying market

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

RS016013

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel